Geisinger research shows that the use of an antimalarial medication may prevent the onset of diabetes in patients with rheumatoid arthritis.
Researchers examined the records of 2,093 Geisinger patients who received treatment for rheumatoid arthritis from 2000 to 2008. The study looked at, among other things, use of the medication hydroxychloroquine (HCQ) and the development of new cases of diabetes in these patients.
HCQ was developed to treat malaria but it has also been used to treat rheumatoid arthritis and other autoimmune diseases.
In patients with rheumatoid arthritis, use of HCQ was associated with a 53 percent reduction in the development of new cases of diabetes, the study found.
‘Given the relative safety and low cost of this generic drug, HCQ may be useful in preventing diabetes in other high risk groups,’ said lead study investigator and Geisinger rheumatologist Androniki Bili, MD, MPH.
Researchers don’t know how exactly HCQ prevents diabetes onset but it’s suspected that HCQ improves glucose tolerance.
People with rheumatoid arthritis are at increased risk for diabetes due to more sedentary lifestyle, chronic inflammation and use of steroid medications that can cause weight gain.
‘We should revisit HCQ in the treatment of rheumatoid arthritis because, in addition to its disease-modifying properties, it might prevent the development of diabetes in this high risk group,’ Dr. Bili said.
Release Date: October 29, 2008
Source: Geisinger Health System
